Our portfolio includes lead candidates in clinical development and a robust preclinical series, all designed to overcome established cancer drug resistance mechanisms.
ATNT-101
ATNT-202
Discovery Series
Phase Ib/IIa candidate targeting treatment-resistant solid tumors. Engineered for high-affinity binding and pathway neutralization.
Preclinical small molecule selectively neutralizing secondary resistance mutations. Advancing towards IND-enabling studies.
Modular structural chemistry engine populating early assets across hard-to-treat targets. Constantly evolving with novel molecular insights.
Molecular Selectivity and Resistance Pathway Neutralization
High-Affinity Target Selectivity
We map exact cellular resistance mechanisms to engineer molecules with unparalleled selectivity, minimizing off-target effects and maximizing therapeutic index.
Neutralizing Refractory Pathways
Our compounds are specifically designed to bypass and neutralize resistance pathways common in refractory solid tumors, offering new hope where current therapies fail.
Access Comprehensive Data Dossiers
For institutional investors, pharmaceutical partners, and research collaborators, full preclinical and clinical data packages are available under mutual NDA.